dose limiting toxicities

Related by string. Dose limiting toxicities * Doses . DOSE . DO Se . DOSES : mg kg dose . tolerated dose MTD . label dose escalation . dose escalation study / limited . limits . Limits . Limiting : Limited Brands Inc. . Holdings Limited . Flow Through Limited . Limited Late Model / Toxicities : ERBITUX dermatologic toxicities . overlapping toxicities . hematologic toxicities . intrinsic toxicities * *

Related by context. Frequent words. (Click for all words.) 79 limiting toxicity 71 tolerated dose MTD 67 myelosuppression 66 toxicities 66 hypercalcemia 65 antitumor activity 65 laboratory abnormalities 65 HGS ETR1 64 pharmacodynamic 64 discontinuations 64 thrombocytopenia 64 events AEs 64 evaluable patients 63 febrile neutropenia 63 SAEs 63 Phase 2a trial 63 dose escalation 62 pharmacokinetic profile 62 evaluable 62 CA4P 62 dasatinib 62 Adverse events 62 tolerability 61 neurotoxicity 61 tumor regression 61 mcg kg 61 Phase Ib 61 Phase 1b 61 IMGN# 61 mg BID 61 treatment emergent adverse 61 hepatotoxicity 61 mg/m2 60 hypersensitivity reactions 60 plasma concentrations 60 mg dose 60 adalimumab 60 composite endpoint 60 NGX# 60 Tolerability 60 antiviral activity 60 eculizumab 60 Azixa 60 certolizumab pegol 59 dosing schedules 59 GRN#L 59 pharmacokinetics 59 tolerability profile 59 dose escalation trial 59 hematologic 59 ACTEMRA 59 LymphoStat B 59 rotigotine 59 CYT# 59 Phase IIa trial 59 elagolix 59 MGCD# [002] 59 safety tolerability 59 efficacy endpoints 59 vandetanib 59 phase IIb 59 dose escalation study 58 XL# [003] 58 infusion reactions 58 talactoferrin 58 bortezomib 58 peginterferon 58 Zerenex 58 PF # [001] 58 pharmacodynamics 58 AP# [003] 58 refractory multiple myeloma 58 TRIOLEX 58 bosentan 58 abatacept 58 placebo controlled trials 58 pegloticase 58 JANUVIA 58 mitoxantrone 58 tumor shrinkage 58 monotherapy 58 clinically meaningful 57 neutropenia 57 AEs 57 pharmacokinetic 57 cytotoxicity 57 IDX# 57 MGCD# [001] 57 GEMZAR 57 ISIS # 57 bevirimat 57 proteinuria 57 Phase 1b clinical 57 label dose escalation 57 Phase IIa clinical 57 eltrombopag 57 leucovorin 57 vinorelbine 57 mucositis 57 belinostat 57 castration resistant prostate cancer

Back to home page